Loading…
Reported covered position: Staff Asst., Legislative Coordinator, Legislative Asst., and Sr. Legislative Asst., to Rep. Fred Upton.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
National Defense Authorization Act for Fiscal Year 2024
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, national security, and privacy issues relating to biopharmaceutical manufacturers; Tax and incentives; Issues related to drug manufacturing and pricing; H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; Issues relating to pandemic preparedness and infectious disease education; Issues relating to utilization management; Issues relating to health care extenders; Issues related to federal contracting relating to biopharmaceutical manufacturers
EPA Accountability to Farm Country Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2026 · third_quarter · Q3
Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration and manufacturing issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Biosimilar issues related to biopharmaceutical manufacturers.
Intellectual property legislation related to biopharmaceutical manufacturers.
Source: Senate LDA
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; Biomedical Advanced Research and Development Authority contract; issues relating to step therapy
EPA Accountability to Farm Country Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; Consolidated Appropriations Act, 2023; issues related to the Prescription Drug User Fee Act
EPA Accountability to Farm Country Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; issues relating to step therapy
EPA Accountability to Farm Country Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; Biomedical Advanced Research and Development Authority contract; issues relating to step therapy; issues relating to development of COVID therapeutics; issues relating to health care extenders
Affordable Insulin Now Act of 2023
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; Biomedical Advanced Research and Development Authority contract; issues relating to step therapy
Affordable Insulin Now Act of 2023
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; issues relating to step therapy
Affordable Insulin Now Act of 2023
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; Consolidated Appropriations Act, 2023; issues related to the Prescription Drug User Fee Act
Inflation Reduction Act of 2022
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; Consolidated Appropriations Act, 2023; issues related to the Prescription Drug User Fee Act
Inflation Reduction Act of 2022
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
Inflation Reduction Act of 2022
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022
Food and Drug Amendments of 2022
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
Food and Drug Amendments of 2022
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022
National Defense Authorization Act for Fiscal Year 2023
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
National Defense Authorization Act for Fiscal Year 2023
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022
PREVENT Pandemics Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
FDASLA Act of 2022
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022
FDASLA Act of 2022
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
Elijah E. Cummings Lower Drug Costs Now Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Medicare issues relating to biopharmaceutical manufacturers; Medicare and Medicaid payment policies; bills relating to drug pricing and Medicare Part B including H.R. 3 and S. 2543
Prescription Drug Pricing Reduction Act of 2019
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Medicare issues relating to biopharmaceutical manufacturers; Medicare and Medicaid payment policies; bills relating to drug pricing and Medicare Part B including H.R. 3 and S. 2543
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers.
Tax and inflation issues related to corporations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2026 · second_quarter · Q2
Tax and inflation issues related to corporations.
Intellectual property legislation related to biopharmaceutical manufacturers.
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers.
Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2026 · first_quarter · Q1
Patent issues relating to biopharmaceutical manufacturers; Intellectual property legislation related to biopharmaceutical manufacturers; Issues relating to WTO TRIPS waivers.
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers.
Tax and inflation issues related to corporations.
Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Issues related to defense spending; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2025 · fourth_quarter · Q4
Tax and inflation issues related to corporations.
Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Issues related to defense spending; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program.
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers.
Patent issues relating to biopharmaceutical manufacturers; Intellectual property legislation related to biopharmaceutical manufacturers; Issues relating to WTO TRIPS waivers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2025 · third_quarter · Q3
Tax and inflation issues related to corporations.
Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Issues related to defense spending; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program.
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers.
Patent issues relating to biopharmaceutical manufacturers; Intellectual property legislation related to biopharmaceutical manufacturers; Issues relating to WTO TRIPS waivers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2025 · second_quarter · Q2
Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Issues related to defense spending; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program.
Tax and inflation issues related to corporations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2025 · first_quarter · Q1
Tax and inflation issues related to corporations.
Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; National Defense Authorization Act; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2024 · fourth_quarter · Q4
Biodefense, FDA, national security, and privacy issues relating to biopharmaceutical manufacturers; Tax and incentives; Issues related to drug manufacturing and pricing; H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; Issues relating to pandemic preparedness and infectious disease education; Issues relating to utilization management; Issues relating to health care extenders; Issues related to federal contracting relating to biopharmaceutical manufacturers
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2024 · third_quarter · Q3
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2024 · second_quarter · Q2
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2024 · first_quarter · Q1
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2023 · fourth_quarter · Q4
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; Biomedical Advanced Research and Development Authority contract; issues relating to step therapy; issues relating to development of COVID therapeutics; issues relating to health care extenders
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2023 · third_quarter · Q3
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; Biomedical Advanced Research and Development Authority contract; issues relating to step therapy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2023 · second_quarter · Q2
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; issues relating to step therapy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2023 · first_quarter · Q1
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; Consolidated Appropriations Act, 2023; issues related to the Prescription Drug User Fee Act
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2022 · fourth_quarter · Q4
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers, including ancillary care and prior authorization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2022 · third_quarter · Q3
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers, including ancillary care
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2022 · second_quarter · Q2
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
Medicare and Medicaid issues relating to biopharmaceutical manufacturers, including ancillary care
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2022 · first_quarter · Q1
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
Medicare and Medicaid issues relating to biopharmaceutical manufacturers, including ancillary care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2021 · fourth_quarter · Q4
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
Medicare and Medicaid issues relating to biopharmaceutical manufacturers, including ancillary care
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2021 · third_quarter · Q3
Medicare and Medicaid issues relating to biopharmaceutical manufacturers, including ancillary care
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2021 · second_quarter · Q2
Medicare and Medicaid issues relating to biopharmaceutical manufacturers, including ancillary care
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2021 · first_quarter · Q1
Medicare and Medicaid issues relating to biopharmaceutical manufacturers, including ancillary care
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2020 · fourth_quarter · Q4
Medicare and Medicaid issues relating to biopharmaceutical manufacturers, including ancillary care
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2020 · third_quarter · Q3
Medicare and Medicaid issues relating to biopharmaceutical manufacturers
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing; pandemic response measures, including manufacturing and budget appropriation issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of the Vice President of the United States, SENATE, White House Office
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2020 · second_quarter · Q2
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing; pandemic response measures
Medicare issues relating to biopharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2020 · first_quarter · Q1
Medicare issues relating to biopharmaceutical manufacturers; Medicare and Medicaid payment policies; bills relating to drug pricing and Medicare Part B including H.R. 3 and S. 2543
Biodefense issues relating to biopharmaceutical manufacturers; pandemic readiness and response
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of the Vice President of the United States, SENATE, White House Office
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2019 · fourth_quarter · Q4
Medicare issues relating to biopharmaceutical manufacturers; Medicare and Madicaid payment policies; drug pricing
Bio-defense issues relating to bio-pharmaceutical manufacturers; issues related to opioids; issues related to biopharmceutical sector, innovation, patient access and health care manufacturing; issues related to healthcare reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2019 · third_quarter · Q3
Issues relating to bio-preparedness; Regulatory and appropriations issues relating to HHS; Issues relating to prescription drug pricing and payment reforms.
Medicare issues relating to biopharmaceutical manufacturers.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE